Posts

European VCs Launch Life Sciences Coalition to Boost Homegrown Biotech Investment

The European Life Sciences Coalition (ELSC) launched in Brussels in association with Invest Europe to strengthen Europe's biotech and life sciences VC ecosystem by mobilizing public and private capital. 1 3 Members include heavyweight VCs like Novo Holdings , Sofinnova Partners , Forbion , Omega Funds , HealthCap , law firms Cooley and Covington & Burling , and the Flanders Institute for Biotechnology (VIB ). 1 2 4 5 Coalition members manage over €24 billion in life sciences assets and have invested in or founded more than 1,400 companies . 1 3 5 ELSC aims to address challenges like fragmented capital markets, regulatory hurdles, and low European VC share (7% globally vs. 63% US), pushing biotechs to list outside EU, by lobbying policymakers for reforms. 1 4 5 The coalition focuses on structural reforms, not subsidies, to retain innovation in Europe and engage on initiatives like the EU Biotech Act. 4 5 Sources: 1. https://www.fiercebiotech.com/biotech/european-l...

BridgeBio's Infigratinib Succeeds in Phase 3 Trial for Achondroplasia Dwarfism

Sanofi Replaces CEO Paul Hudson with Belén Garijo Amid Pipeline Setbacks

PTC Therapeutics Withdraws US NDA for Translarna in Nonsense Mutation Duchenne Muscular Dystrophy

NervGen Pharma Announces Retirement of CFO Bill Adams

Aardvark Therapeutics Announces Leadership Appointments

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Bio-Rad Laboratories Reports Q4 and Full-Year 2025 Financial Results: Revenue Growth Amid Segment Challenges

Friday Five: Novo Nordisk Sues Hims & Hers Over Compounded GLP-1 Drugs Amid FDA Crackdown

Friday Five: Novo Nordisk Sues Hims & Hers Over Compounded GLP-1 Drugs Amid FDA Crackdown

Novo Nordisk Plans Expansion of Irish Facility in Athlone for Wegovy Pill Production

Terray Therapeutics Unveils TerraBind AI Model: 20% More Accurate and 26x Faster Than Boltz-2 in Protein Binding Prediction

Oral Wegovy Attracts Thousands of New GLP-1 Patients